BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31764220)

  • 21. MiT family translocation renal cell carcinoma.
    Argani P
    Semin Diagn Pathol; 2015 Mar; 32(2):103-13. PubMed ID: 25758327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.
    Argani P; LaƩ M; Hutchinson B; Reuter VE; Collins MH; Perentesis J; Tomaszewski JE; Brooks JS; Acs G; Bridge JA; Vargas SO; Davis IJ; Fisher DE; Ladanyi M
    Am J Surg Pathol; 2005 Feb; 29(2):230-40. PubMed ID: 15644781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
    Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
    Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.
    Argani P; Zhang L; Reuter VE; Tickoo SK; Antonescu CR
    Am J Surg Pathol; 2017 May; 41(5):655-662. PubMed ID: 28296677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
    Kato I; Furuya M; Baba M; Kameda Y; Yasuda M; Nishimoto K; Oyama M; Yamasaki T; Ogawa O; Niino H; Nakaigawa N; Yano Y; Sakamoto K; Urata Y; Mikami K; Yamasaki S; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Histopathology; 2019 Aug; 75(2):254-265. PubMed ID: 30908700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
    Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
    Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translocation renal cell carcinomas in adults: a single-institution experience.
    Zhong M; De Angelo P; Osborne L; Paniz-Mondolfi AE; Geller M; Yang Y; Linehan WM; Merino MJ; Cordon-Cardo C; Cai D
    Am J Surg Pathol; 2012 May; 36(5):654-62. PubMed ID: 22446944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
    Wang XT; Xia QY; Ye SB; Wang X; Li R; Fang R; Shi SS; Zhang RS; Tan X; Chen JY; Sun K; Teng XD; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Mod Pathol; 2018 Sep; 31(9):1346-1360. PubMed ID: 29713041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas.
    Mosquera JM; Dal Cin P; Mertz KD; Perner S; Davis IJ; Fisher DE; Rubin MA; Hirsch MS
    Diagn Mol Pathol; 2011 Sep; 20(3):129-37. PubMed ID: 21817901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features.
    Rao Q; Zhang XM; Tu P; Xia QY; Shen Q; Zhou XJ; Shi QL
    Int J Clin Exp Pathol; 2013; 6(7):1452-7. PubMed ID: 23826432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.
    CaliĆ² A; Brunelli M; Segala D; Pedron S; Tardanico R; Remo A; Gobbo S; Meneghelli E; Doglioni C; Hes O; Zampini C; Argani P; Martignoni G
    Mod Pathol; 2018 Mar; 31(3):474-487. PubMed ID: 29052596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melanotic MiT family translocation neoplasms: Expanding the clinical and molecular spectrum of this unique entity of tumors.
    Saleeb RM; Srigley JR; Sweet J; Doucet C; Royal V; Chen YB; Brimo F; Evans A
    Pathol Res Pract; 2017 Nov; 213(11):1412-1418. PubMed ID: 28969862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDCT findings of renal cell carcinoma associated with Xp11.2 translocation and TFE3 gene fusion and papillary renal cell carcinoma.
    Woo S; Kim SY; Lee MS; Moon KC; Kim SH; Cho JY; Kim SH
    AJR Am J Roentgenol; 2015 Mar; 204(3):542-9. PubMed ID: 25714283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
    Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
    Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
    Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
    Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.
    Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Fukumura Y; Nagashima Y; Argani P; Yao T
    Int J Clin Exp Pathol; 2013; 6(11):2585-90. PubMed ID: 24228124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature.
    Peckova K; Vanecek T; Martinek P; Spagnolo D; Kuroda N; Brunelli M; Vranic S; Djuricic S; Rotterova P; Daum O; Kokoskova B; Vesela P; Pivovarcikova K; Bauleth K; Dubova M; Kalusova K; Hora M; Michal M; Hes O
    Ann Diagn Pathol; 2014 Dec; 18(6):351-7. PubMed ID: 25438924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A primary rectal neoplasm with novel DDX5-TFEB fusion.
    Zhang M; Yin X; Chen J; Zhu S; Zheng L; Zeng H; Zhou Q; Chen N
    Virchows Arch; 2022 Sep; 481(3):511-516. PubMed ID: 35397700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Xp11 translocation renal cell carcinoma with morphological features mimicking multilocular cystic renal neoplasm of low malignant potential: a series of six cases with molecular analysis.
    Song Y; Yin X; Xia Q; Zheng L; Yao J; Zeng H; Nie L; Gong J; Zhou Q; Chen N
    J Clin Pathol; 2021 Mar; 74(3):171-176. PubMed ID: 32699116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.